A COVID-19 vaccine candidate being produced by biotech company Moderna has shown to be 94.5% effective in Phase 3 clinical trials, the company said Monday.
The news means that the company is on track to request Emergency Use Authorization status for the drug in the coming weeks. The vaccine is already being mass-produced and thousands of doses will be ready to ship following authorization.
Listen Live
